MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes

Title
MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes
Authors
판철호무스타파 바드르Marwa Anwar MohamedMarwa Ahmed MadkourMohammed Mohammed ShamseyaNoha Mahmoud IssaAhmed Noah BadrDoaa Ahmed Ghareeb
Keywords
MicroRNA; Hepatocellular carcinoma; Type 2 diabetes; Nonalcoholic fatty liver disease
Issue Date
2019-11
Publisher
WORLD JOURNAL OF GASTROENTEROLOGY
Citation
VOL 25, NO 42-6341
Abstract
BACKGROUND Nonalcoholic steatohepatitis-related cirrhosis is one of the liver complications in type 2 diabetes mellitus (T2DM) and reported to be a risk factor for developing hepatocellular carcinoma (HCC). A reliable screening biomarker of liver cirrhosis (LC) and HCC among T2DM patients is important to reduce the morbidity and mortality of this disease. MicroRNA (miRNA) is considered a key player in HCC and T2DM, and it might be a hidden culprit in diabetes-associated HCC, making it a promising reliable prognostic tool. AIM To investigate the signature of serum miRNAs as early biomarkers for the screening of HCC among diabetic patients. METHODS Expression profiles of miRNAs in serum samples of diabetic LC and diabetic HCC patients were assessed using Illumina sequencing; then, RT-qPCR was used to validate significantly altered miRNAs between the two groups. Candidate miRNAs were tested in serum samples of 200 T2DM patients, 270 LC patients, 200 HCC patients, and 225 healthy control subjects. Additionally, receiver operating characteristic (ROC) analysis, with area under the curve (AUC), was performed to assess the diagnostic performance of the screened miRNAs for discriminating HCC from LC and nonmalignant patients (LC + T2DM). RESULTS Expression of the sequenced miRNAs in serum was different in HCC vs LCpositive T2DM patients. Two miRNAs (miR-34a, miR-221) were significantly upregulated and five miRNAs (miR-16, miR-23-3p, miR-122-5p, miR-198, miR-199a-3p) were significantly down-regulated in HCC compared to LC patients. Analysis of ROC curve demonstrated that the combination of these seven miRNAs can be used as a reliable biomarker for detection of HCC in diabetic patients, as it could identify HCC with high diagnostic accuracy in diabetic LC patients (AUC = 0.993) and in diabetic nonmalignant patients (AUC = 0.961). CONCLUSION This study validates a panel of serum miRNAs that can be used as a reliable
URI
http://pubs.kist.re.kr/handle/201004/70381
ISSN
1007-9327
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE